喘可治注射液治疗儿童支气管哮喘的临床研究  

Clinical Study on Effect of Chuankezhi Injection in Treating Children with Bronchial Asthma

作　　者：赵建琴[1] 邵洁[1] 钟文伟[1] 高正仪[1] 王愚珍[1] 王蓓蓓[1] 罗海燕[1] 李云珠[1] 俞善昌[1] 

机构地区：[1]上海第二医科大学附属瑞金医院儿科,上海200025

出　　处：《中国中西医结合杂志》2004年第6期511-513,共3页Chinese Journal of Integrated Traditional and Western Medicine

摘　　要：目的研究喘可治注射液对儿童哮喘的临床疗效和安全性。方法 6 8例 5～ 14岁哮喘或哮喘合并过敏性鼻炎患儿 ,随机分为治疗组和对照组 ,治疗组采用喘可治治疗 ,对照组采用银杏注射液治疗 ,观察两组每日症状评分 ,早、晚最大呼气峰流速测定 (PEF) ,肺功能检查 (FEV1)。结果治疗后症状评分中位数治疗组为 6 0 (M 2 5～M 75 :4 9～ 2 1 5 ) ,对照组为 10 0 (M 2 5～M 75 :6 2～ 2 7 5 ) ,两组比较差异有显著性 ;PEF变异率治疗组为 (4 3± 5 1) % ,对照组为 (5 9± 6 7) % ,两组比较差异有显著性 ;FEV1%较对照组显著改善。结论临床研究发现喘可治有助于改善哮喘患儿临床症状 ,降低PEF变异率 ,改善肺功能 。ObjectiveTo evaluate the efficacy and safety of Chuankezhi injection to children with bronchial asthma. MethodsSixty eight children suffered from asthma and/or asthma complicated with allergic rhinitis were randomly divided into the treated group and the control group, who received treatment of Chuankezhi injection and Ginkgo injection respectively. Clinical observation on daily symptom scores, and lung functions as peak expiratory flow (PEF), and forced expiratory volume in one second (FEV 1) were conducted. ResultsAfter treatment the median of symptomatic scores in the treated group was 6.0 (M25-M75:4 9-21 5) and that in the control group was 10 0(M25-M75:6 19-27 5), showing significant difference between groups; significant improvement was shown in the treated group, in which the PEF variance rate was reduced to 4 3±5 1%, while in the control group, it was 5 9±6 7%, the difference between the two groups was significant. Similar result also showed in comparison of FEV 1 rate. ConclusionChuankezhi is helpful in improving clinical symptoms, reducing PEF variance rate and enhancing lung function in children with bronchial asthma, so as to be benefit to the long term stable alleviation of asthma.

关 键 词：喘可治注射液 儿童 支气管哮喘 银杏注射液 

分 类 号：R725.6[医药卫生—儿科]